ArticleNature medicine2021
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.Viruses · 2023Trial
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial.Annals of intensive care · 2024Article
- Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument.Biomarker insights · 2023Article
- Article
- Review
- Hyperinflammation, apoptosis, and organ damage.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).Wiener klinische Wochenschrift · 2022Article
- Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.Clinical and experimental immunology · 2022Observational
- COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.Nature reviews. Rheumatology · 2022Review
- Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.bioRxiv : the preprint server for biology · 2021Article
Corrections and comments
- Erratum for
Authors and funding
64 authors at 20 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.